The Safety and Efficacy of DCA for the Treatment of Brain Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Malignant Gliomas, Glioblastoma Multiforme
Interventions
DRUG

Dichloroacetate (DCA)

Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.

Trial Locations (1)

T6G 2B7

University of Alberta Hospital, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

collaborator

Capital Health, Canada

OTHER

NCT00540176 - The Safety and Efficacy of DCA for the Treatment of Brain Cancer | Biotech Hunter | Biotech Hunter